Imatinib, originally designed as a kinase inhibitor to target the BCR-ABL fusion protein in chronic myeloid leukemia, was later found to also activate the serotonin 4 (5-HT4) receptor, a GPCR associated with gastrointestinal function. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.